DK3208334T3 - Cdc45l-peptider og vacciner, der indbefatter disse - Google Patents

Cdc45l-peptider og vacciner, der indbefatter disse

Info

Publication number
DK3208334T3
DK3208334T3 DK17163532.9T DK17163532T DK3208334T3 DK 3208334 T3 DK3208334 T3 DK 3208334T3 DK 17163532 T DK17163532 T DK 17163532T DK 3208334 T3 DK3208334 T3 DK 3208334T3
Authority
DK
Denmark
Prior art keywords
vaccines including
cdc45l peptides
cdc45l
peptides
vaccines
Prior art date
Application number
DK17163532.9T
Other languages
English (en)
Inventor
Yasuharu Nishimura
Yusuke Tomita
Yusuke Nakamura
Takuya Tsunoda
Original Assignee
Oncotherapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc
Application granted granted Critical
Publication of DK3208334T3 publication Critical patent/DK3208334T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/46432—Nervous system antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/464838—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/55—Lung

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK17163532.9T 2009-05-26 2010-05-25 Cdc45l-peptider og vacciner, der indbefatter disse DK3208334T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21713309P 2009-05-26 2009-05-26
EP10780256.3A EP2435567B1 (en) 2009-05-26 2010-05-25 Cdc45l peptides and vaccines including the same

Publications (1)

Publication Number Publication Date
DK3208334T3 true DK3208334T3 (da) 2019-09-30

Family

ID=43222423

Family Applications (3)

Application Number Title Priority Date Filing Date
DK10780256.3T DK2435567T3 (da) 2009-05-26 2010-05-25 Cdc45l-peptider og vacciner, der indbefatter disse
DK19175920.8T DK3556857T3 (da) 2009-05-26 2010-05-25 Cdc45l-peptider og vacciner, der indeholder disse
DK17163532.9T DK3208334T3 (da) 2009-05-26 2010-05-25 Cdc45l-peptider og vacciner, der indbefatter disse

Family Applications Before (2)

Application Number Title Priority Date Filing Date
DK10780256.3T DK2435567T3 (da) 2009-05-26 2010-05-25 Cdc45l-peptider og vacciner, der indbefatter disse
DK19175920.8T DK3556857T3 (da) 2009-05-26 2010-05-25 Cdc45l-peptider og vacciner, der indeholder disse

Country Status (16)

Country Link
US (1) US8586547B2 (da)
EP (4) EP3556857B1 (da)
JP (1) JP5903697B2 (da)
KR (1) KR101765452B1 (da)
CN (3) CN103694315B (da)
AU (1) AU2010253356B2 (da)
BR (1) BRPI1010666B1 (da)
CA (3) CA3167451A1 (da)
DK (3) DK2435567T3 (da)
ES (3) ES2875950T3 (da)
IL (1) IL216211A (da)
MX (1) MX2011012619A (da)
RU (1) RU2562160C2 (da)
SG (1) SG176058A1 (da)
TW (1) TWI507204B (da)
WO (1) WO2010137295A1 (da)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3122778A1 (en) * 2011-10-28 2013-05-02 Oncotherapy Science, Inc. Topk peptides and vaccines including the same
EP3202783A1 (en) 2016-02-02 2017-08-09 Ecole Polytechnique Federale de Lausanne (EPFL) Engineered antigen presenting cells and uses thereof
CA3047492C (en) 2017-01-25 2024-01-02 Ose Immunotherapeutics Method for manufacturing a stable emulsion for peptide delivery
EP3684822A4 (en) 2017-09-20 2021-06-16 The University of British Columbia NEW ANTI-HLA-A2 ANTIBODIES AND USES THEREOF

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
EP0239102A3 (en) 1986-03-28 1989-07-12 Tsuji, Kimiyoshi Process for the formation of human-human hybridoma
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
DE69133476T2 (de) 1990-08-29 2006-01-05 GenPharm International, Inc., Palo Alto Transgene Mäuse fähig zur Produktion heterologer Antikörper
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5804566A (en) 1993-08-26 1998-09-08 The Regents Of The University Of California Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
US5922687A (en) 1995-05-04 1999-07-13 Board Of Trustees Of The Leland Stanford Junior University Intracellular delivery of nucleic acids using pressure
DE69635895D1 (de) 1995-08-03 2006-05-04 Rijksuniversiteit Te Leiden Le Antigen presentierende bläschen, die von zellen ableiten
US5853719A (en) 1996-04-30 1998-12-29 Duke University Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA
US6294378B1 (en) 1996-07-26 2001-09-25 Sloan-Kettering Institute For Cancer Research Method and reagents for genetic immunization
US20030083461A1 (en) * 1997-06-16 2003-05-01 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
FR2766205B1 (fr) 1997-07-16 2002-08-30 Inst Nat Sante Rech Med Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede
EP1090924B8 (en) 1998-06-25 2007-11-21 Green Peptide Co., Ltd. Tumor antigen peptides originating in cyclophilin b
CA2440773A1 (en) 2001-03-14 2002-09-19 Dakocytomation Denmark A/S Novel mhc molecule constructs, and methods of employing these constructs for diagnosis and therapy, and uses of mhc molecules
CA2399569A1 (en) 2001-09-25 2003-03-25 Yusuke Nakamura Diagnostic markers and drug targets for treatment of cancer
GB2392158B (en) 2002-08-21 2005-02-16 Proimmune Ltd Chimeric MHC protein and oligomer thereof
ATE531729T1 (de) * 2002-09-12 2011-11-15 Oncotherapy Science Inc Kdr-peptide und diese enthaltende impfstoffe
US7915036B2 (en) 2004-09-13 2011-03-29 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Compositions comprising T cell receptors and methods of use thereof
JP4370409B2 (ja) 2005-06-22 2009-11-25 国立大学法人東北大学 がんの予後予測方法
US20090317392A1 (en) 2005-07-27 2009-12-24 Yusuke Nakamura Method of diagnosing small cell lung cancer
EP2311986B1 (en) 2005-07-27 2015-04-15 Oncotherapy Science, Inc. Method of diagnosing esophageal cancer
US8003770B2 (en) 2005-09-13 2011-08-23 Mie University T-cell receptor and nucleic acid encoding the receptor
ES2365077T3 (es) * 2006-06-16 2011-09-21 Onco Therapy Science, Inc. Péptido antígeno anticáncer derivado de sparc y composición farmacéutica que comprende el mismo.
US8470534B2 (en) 2006-12-01 2013-06-25 Erik S. Knudsen Methods of predicting resistance or sensitivity to therapies for cancer
TWI441648B (zh) * 2007-01-03 2014-06-21 Oncotherapy Science Inc Ｆｏｘｐ３胜肽疫苗

Also Published As

Publication number Publication date
ES2875950T3 (es) 2021-11-11
IL216211A (en) 2016-06-30
EP2435567A1 (en) 2012-04-04
BRPI1010666A2 (pt) 2017-09-12
EP2435567B1 (en) 2017-05-03
CN102459589B (zh) 2013-12-25
KR101765452B1 (ko) 2017-08-07
CA2762934A1 (en) 2010-12-02
EP3868778A2 (en) 2021-08-25
ES2746334T3 (es) 2020-03-05
IL216211A0 (en) 2012-01-31
RU2011152975A (ru) 2013-07-10
EP3208334A2 (en) 2017-08-23
WO2010137295A1 (en) 2010-12-02
CN105153279A (zh) 2015-12-16
EP3208334B1 (en) 2019-07-03
KR20120018203A (ko) 2012-02-29
US8586547B2 (en) 2013-11-19
MX2011012619A (es) 2012-01-30
EP3208334A3 (en) 2017-10-18
EP3556857A3 (en) 2019-12-04
CN103694315A (zh) 2014-04-02
CA3011607C (en) 2022-09-13
CN105153279B (zh) 2018-09-11
CN103694315B (zh) 2015-07-29
JP2012527867A (ja) 2012-11-12
US20120164163A1 (en) 2012-06-28
SG176058A1 (en) 2011-12-29
ES2631952T3 (es) 2017-09-06
AU2010253356B2 (en) 2015-09-24
TWI507204B (zh) 2015-11-11
CA2762934C (en) 2018-09-04
CA3167451A1 (en) 2010-12-02
BRPI1010666B1 (pt) 2021-11-23
RU2562160C2 (ru) 2015-09-10
JP5903697B2 (ja) 2016-04-20
EP3556857B1 (en) 2021-05-05
EP3556857A2 (en) 2019-10-23
AU2010253356A1 (en) 2011-12-01
DK2435567T3 (da) 2017-07-24
TW201106962A (en) 2011-03-01
CN102459589A (zh) 2012-05-16
DK3556857T3 (da) 2021-07-12
EP2435567A4 (en) 2013-03-13
EP3868778A3 (en) 2021-11-03
CA3011607A1 (en) 2010-12-02

Similar Documents

Publication Publication Date Title
DK2552434T3 (da) Peptider og anvendelse deraf
DK3572091T3 (da) Modificerede relaxinpolypeptider og anvendelser deraf
DK3663399T3 (da) Modificerede factor IX-polypeptider og anvendelser deraf
DK3321287T3 (da) Fusionsproteiner og kombinationsvacciner
DK2567240T4 (da) Lipidomiske biomarkører til aterosklerose og kardiovaskulær sygdom
DK3339323T3 (da) Anti-n3pglu-amyloid-beta-peptid-antistoffer og anvendelser deraf
DK2320911T3 (da) Vasokonstriktionspræparater og fremgangsmåder til anvendelse deraf
DK2726092T3 (da) Serpin-fusionspolypeptider og fremgangsmåder til anvendelse deraf
DK3305492T3 (da) Kompositmaterialer og tilhørende fremgangsmåder
DK2472150T3 (da) System og ventilenhed
DK2914291T3 (da) Anti-komplement-c1s-antistoffer og anvendelser deraf
DK3045187T3 (da) Injektor og fremgangsmåde til samling
DK2467173T3 (da) Sårbandager, fremgangsmåder til anvendelse heraf og fremgangsmåder til dannelse deraf
DK2536830T3 (da) Polypeptider
DK2624866T3 (da) Tumorspecifikke antistoffer og anvendelser deraf
DK2361704T4 (da) Metalmultifasemateriale og fremgangsmåde til fremstilling deraf
DK3168229T3 (da) Fremstilling af proteiner og polypeptider.
DK2584921T3 (da) Sondeernæringspakninger og fremgangsmåder til anvendelse deraf
DK3197164T3 (da) Afkodningsanordning og afkodningsfremgangsmåde
DK2573550T3 (da) Stofinspektionsindretning og inspektionsfremgangsmåde
DK2384327T3 (da) Forbindelse med kondenseret ring og anvendelse deraf.
DK2344523T3 (da) Gas-kombinationsvacciner og lægemidler
DK3001686T3 (da) Indretning, fremgangsmåde og program til biprædiktiv billedafkodning
BRPI0915367A2 (pt) peptídeos e epítopos anti-p2x7
DK3173102T3 (da) FGFR-FC-fusionsprotein og anvendelse deraf